Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report released on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Aptevo Therapeutics Stock Down 3.4 %

Aptevo Therapeutics stock opened at $0.17 on Thursday. Aptevo Therapeutics has a 12-month low of $0.14 and a 12-month high of $21.56. The firm’s fifty day moving average price is $0.37 and its 200 day moving average price is $1.30.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.26. Equities analysts anticipate that Aptevo Therapeutics will post -4.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.